Patents Assigned to Taiwan Advance Bio-Pharm Inc.
  • Recombinant TAT-HOXB4H protein for use as a stimulant of hematopoiesis in vivo
    Patent number: 8450458
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: May 28, 2013
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
    Patent number: 8222206
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: July 17, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Method of enhancing the mobilization of hematopoietic stem cells using TAT-HOXB4H
    Patent number: 8222207
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: July 17, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang
  • Method of producing TAT-HOXB4H
    Patent number: 8124377
    Abstract: The present invention relates to a new and nonobvious method of producing the C-terminal histidine tagged TAT-HOXB4 fusion protein (TAT-HOXB4H), providing unexpected benefits of increased yield and stability to allow for in vivo administration of this protein, and pharmaceutical composition comprising an effective ingredient, TAT-HOXB4H, having stimulatory activity on the production of hematopoietic cells. More specifically, recombinant TAT-HOXB4H protein enhances engraftment of bone marrow transplants, hematopoietic reconstruction, bone marrow re-population and number of circulating stem cells, particularly after chemotherapy or irradiation.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: February 28, 2012
    Assignee: Taiwan Advance Bio-Pharm Inc.
    Inventors: Kou-Juey Wu, Chi-Hung Huang